ES2203803T3 - Terapias para la insuficiencia renal cronica. - Google Patents

Terapias para la insuficiencia renal cronica.

Info

Publication number: ES2203803T3
Authority: ES; Spain
Prior art keywords: mammal; renal; gfr; mentioned; chronic
Prior art date: 1996-05-06
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

ES97923567T

Other languages

English (en)

Spanish (es)

Inventor

Kuber T. Sampath

Charles M. Cohen

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Curis Inc

Original Assignee

Curis Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-05-06

Filing date

1997-05-06

Publication date

2004-04-16

1997-05-06 Application filed by Curis Inc filed Critical Curis Inc

2004-04-16 Application granted granted Critical

2004-04-16 Publication of ES2203803T3 publication Critical patent/ES2203803T3/es

2017-05-06 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

208000020832 chronic kidney disease Diseases 0.000 title claims abstract description 65
238000002560 therapeutic procedure Methods 0.000 title description 26
102000004169 proteins and genes Human genes 0.000 claims abstract description 55
108090000623 proteins and genes Proteins 0.000 claims abstract description 55
208000022831 chronic renal failure syndrome Diseases 0.000 claims abstract description 49
239000003814 drug Substances 0.000 claims abstract description 48
238000011282 treatment Methods 0.000 claims abstract description 34
230000002188 osteogenic effect Effects 0.000 claims abstract description 7
102000007350 Bone Morphogenetic Proteins Human genes 0.000 claims abstract description 6
108010007726 Bone Morphogenetic Proteins Proteins 0.000 claims abstract description 6
229940112869 bone morphogenetic protein Drugs 0.000 claims abstract description 5
DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 claims description 62
235000018102 proteins Nutrition 0.000 claims description 52
241000124008 Mammalia Species 0.000 claims description 48
210000003734 kidney Anatomy 0.000 claims description 45
108010049870 Bone Morphogenetic Protein 7 Proteins 0.000 claims description 44
230000003907 kidney function Effects 0.000 claims description 34
229940109239 creatinine Drugs 0.000 claims description 31
210000002966 serum Anatomy 0.000 claims description 25
230000001684 chronic effect Effects 0.000 claims description 24
241000282414 Homo sapiens Species 0.000 claims description 19
210000004899 c-terminal region Anatomy 0.000 claims description 18
108090000765 processed proteins & peptides Proteins 0.000 claims description 18
235000018417 cysteine Nutrition 0.000 claims description 17
229920001184 polypeptide Polymers 0.000 claims description 17
102000004196 processed proteins & peptides Human genes 0.000 claims description 17
239000003550 marker Substances 0.000 claims description 15
208000001647 Renal Insufficiency Diseases 0.000 claims description 14
230000037396 body weight Effects 0.000 claims description 14
230000007423 decrease Effects 0.000 claims description 14
201000006370 kidney failure Diseases 0.000 claims description 14
101000899361 Homo sapiens Bone morphogenetic protein 7 Proteins 0.000 claims description 12
206010020880 Hypertrophy Diseases 0.000 claims description 12
238000000502 dialysis Methods 0.000 claims description 12
102000046107 human BMP7 Human genes 0.000 claims description 12
238000012360 testing method Methods 0.000 claims description 12
208000034189 Sclerosis Diseases 0.000 claims description 9
206010020772 Hypertension Diseases 0.000 claims description 8
210000000988 bone and bone Anatomy 0.000 claims description 8
230000001434 glomerular Effects 0.000 claims description 8
206010061989 glomerulosclerosis Diseases 0.000 claims description 8
230000006872 improvement Effects 0.000 claims description 8
239000013049 sediment Substances 0.000 claims description 8
102100022545 Bone morphogenetic protein 8B Human genes 0.000 claims description 7
229940079593 drug Drugs 0.000 claims description 7
230000001631 hypertensive effect Effects 0.000 claims description 7
102100024506 Bone morphogenetic protein 2 Human genes 0.000 claims description 6
102100024504 Bone morphogenetic protein 3 Human genes 0.000 claims description 6
102100024505 Bone morphogenetic protein 4 Human genes 0.000 claims description 6
102100022526 Bone morphogenetic protein 5 Human genes 0.000 claims description 6
102100022525 Bone morphogenetic protein 6 Human genes 0.000 claims description 6
102100040892 Growth/differentiation factor 2 Human genes 0.000 claims description 6
101000762366 Homo sapiens Bone morphogenetic protein 2 Proteins 0.000 claims description 6
101000762375 Homo sapiens Bone morphogenetic protein 3 Proteins 0.000 claims description 6
101000762379 Homo sapiens Bone morphogenetic protein 4 Proteins 0.000 claims description 6
101000899388 Homo sapiens Bone morphogenetic protein 5 Proteins 0.000 claims description 6
101000899390 Homo sapiens Bone morphogenetic protein 6 Proteins 0.000 claims description 6
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
201000000523 end stage renal failure Diseases 0.000 claims description 6
238000007912 intraperitoneal administration Methods 0.000 claims description 6
238000001990 intravenous administration Methods 0.000 claims description 6
201000009925 nephrosclerosis Diseases 0.000 claims description 6
208000007342 Diabetic Nephropathies Diseases 0.000 claims description 5
101000893585 Homo sapiens Growth/differentiation factor 2 Proteins 0.000 claims description 5
-1 OP-3 Proteins 0.000 claims description 5
206010038468 Renal hypertrophy Diseases 0.000 claims description 5
208000033679 diabetic kidney disease Diseases 0.000 claims description 5
201000010099 disease Diseases 0.000 claims description 5
208000028208 end stage renal disease Diseases 0.000 claims description 5
201000008627 kidney hypertrophy Diseases 0.000 claims description 5
208000024985 Alport syndrome Diseases 0.000 claims description 4
206010018367 Glomerulonephritis chronic Diseases 0.000 claims description 4
230000022159 cartilage development Effects 0.000 claims description 4
206010012601 diabetes mellitus Diseases 0.000 claims description 4
230000006870 function Effects 0.000 claims description 4
208000003215 hereditary nephritis Diseases 0.000 claims description 4
206010038433 renal dysplasia Diseases 0.000 claims description 4
238000010171 animal model Methods 0.000 claims description 3
239000002775 capsule Substances 0.000 claims description 3
238000011862 kidney biopsy Methods 0.000 claims description 3
238000004519 manufacturing process Methods 0.000 claims description 3
201000002793 renal fibrosis Diseases 0.000 claims description 3
238000002604 ultrasonography Methods 0.000 claims description 3
230000002485 urinary effect Effects 0.000 claims description 3
208000022461 Glomerular disease Diseases 0.000 claims description 2
238000002591 computed tomography Methods 0.000 claims description 2
238000011321 prophylaxis Methods 0.000 claims description 2
150000001945 cysteines Chemical class 0.000 claims 7
125000003275 alpha amino acid group Chemical group 0.000 claims 6
238000002595 magnetic resonance imaging Methods 0.000 claims 1
230000001002 morphogenetic effect Effects 0.000 claims 1
238000000034 method Methods 0.000 abstract description 25
102000004887 Transforming Growth Factor beta Human genes 0.000 abstract 1
108090001012 Transforming Growth Factor beta Proteins 0.000 abstract 1
238000012959 renal replacement therapy Methods 0.000 abstract 1
ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 abstract 1
241000700159 Rattus Species 0.000 description 50
229940124597 therapeutic agent Drugs 0.000 description 36
150000001413 amino acids Chemical group 0.000 description 22
210000002700 urine Anatomy 0.000 description 21
230000000750 progressive effect Effects 0.000 description 19
239000003795 chemical substances by application Substances 0.000 description 18
210000000885 nephron Anatomy 0.000 description 18
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 14
125000000151 cysteine group Chemical class N[C@@H](CS)C(=O)* 0.000 description 13
241001465754 Metazoa Species 0.000 description 12
210000004027 cell Anatomy 0.000 description 12
150000001875 compounds Chemical class 0.000 description 11
210000005084 renal tissue Anatomy 0.000 description 10
210000001519 tissue Anatomy 0.000 description 10
239000007924 injection Substances 0.000 description 9
238000002347 injection Methods 0.000 description 9
230000001965 increasing effect Effects 0.000 description 8
238000005259 measurement Methods 0.000 description 8
238000013059 nephrectomy Methods 0.000 description 8
230000002829 reductive effect Effects 0.000 description 8
230000001225 therapeutic effect Effects 0.000 description 8
239000004202 carbamide Substances 0.000 description 7
230000024924 glomerular filtration Effects 0.000 description 7
238000006467 substitution reaction Methods 0.000 description 7
210000005239 tubule Anatomy 0.000 description 7
102100035368 Growth/differentiation factor 6 Human genes 0.000 description 6
235000001014 amino acid Nutrition 0.000 description 6
229940024606 amino acid Drugs 0.000 description 6
102100035363 Growth/differentiation factor 7 Human genes 0.000 description 5
238000001574 biopsy Methods 0.000 description 5
238000004140 cleaning Methods 0.000 description 5
230000034994 death Effects 0.000 description 5
230000008034 disappearance Effects 0.000 description 5
239000000203 mixture Substances 0.000 description 5
239000000126 substance Substances 0.000 description 5
108010090254 Growth Differentiation Factor 5 Proteins 0.000 description 4
102100035379 Growth/differentiation factor 5 Human genes 0.000 description 4
230000003247 decreasing effect Effects 0.000 description 4
238000003745 diagnosis Methods 0.000 description 4
239000003792 electrolyte Substances 0.000 description 4
238000001631 haemodialysis Methods 0.000 description 4
230000000322 hemodialysis Effects 0.000 description 4
235000013336 milk Nutrition 0.000 description 4
210000004080 milk Anatomy 0.000 description 4
239000008267 milk Substances 0.000 description 4
238000002360 preparation method Methods 0.000 description 4
239000000047 product Substances 0.000 description 4
239000011734 sodium Substances 0.000 description 4
239000000243 solution Substances 0.000 description 4
230000003068 static effect Effects 0.000 description 4
238000005303 weighing Methods 0.000 description 4
206010002329 Aneurysm Diseases 0.000 description 3
241000283690 Bos taurus Species 0.000 description 3
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
108010090250 Growth Differentiation Factor 6 Proteins 0.000 description 3
102100040898 Growth/differentiation factor 11 Human genes 0.000 description 3
101710204283 Growth/differentiation factor 7 Proteins 0.000 description 3
229920001202 Inulin Polymers 0.000 description 3
208000009857 Microaneurysm Diseases 0.000 description 3
239000002253 acid Substances 0.000 description 3
230000001154 acute effect Effects 0.000 description 3
230000006978 adaptation Effects 0.000 description 3
238000003556 assay Methods 0.000 description 3
230000004071 biological effect Effects 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
239000008280 blood Substances 0.000 description 3
230000001447 compensatory effect Effects 0.000 description 3
230000006378 damage Effects 0.000 description 3
239000012530 fluid Substances 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
230000001939 inductive effect Effects 0.000 description 3
JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 3
229940029339 inulin Drugs 0.000 description 3
210000005075 mammary gland Anatomy 0.000 description 3
108020004707 nucleic acids Proteins 0.000 description 3
102000039446 nucleic acids Human genes 0.000 description 3
150000007523 nucleic acids Chemical class 0.000 description 3
230000036961 partial effect Effects 0.000 description 3
230000036470 plasma concentration Effects 0.000 description 3
230000009467 reduction Effects 0.000 description 3
208000024891 symptom Diseases 0.000 description 3
238000002054 transplantation Methods 0.000 description 3
239000002699 waste material Substances 0.000 description 3
208000009304 Acute Kidney Injury Diseases 0.000 description 2
241001156002 Anthonomus pomorum Species 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
102100028726 Bone morphogenetic protein 10 Human genes 0.000 description 2
241000282472 Canis lupus familiaris Species 0.000 description 2
102100040897 Embryonic growth/differentiation factor 1 Human genes 0.000 description 2
241000283086 Equidae Species 0.000 description 2
208000035126 Facies Diseases 0.000 description 2
108010090296 Growth Differentiation Factor 1 Proteins 0.000 description 2
108010041881 Growth Differentiation Factor 10 Proteins 0.000 description 2
108010090293 Growth Differentiation Factor 3 Proteins 0.000 description 2
102100040895 Growth/differentiation factor 10 Human genes 0.000 description 2
101710194452 Growth/differentiation factor 11 Proteins 0.000 description 2
102100035364 Growth/differentiation factor 3 Human genes 0.000 description 2
101000695367 Homo sapiens Bone morphogenetic protein 10 Proteins 0.000 description 2
101001023964 Homo sapiens Growth/differentiation factor 6 Proteins 0.000 description 2
101001023968 Homo sapiens Growth/differentiation factor 7 Proteins 0.000 description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
102000003982 Parathyroid hormone Human genes 0.000 description 2
108090000445 Parathyroid hormone Proteins 0.000 description 2
108010076504 Protein Sorting Signals Proteins 0.000 description 2
208000033626 Renal failure acute Diseases 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
241000019011 Tasa Species 0.000 description 2
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
201000011040 acute kidney failure Diseases 0.000 description 2
208000012998 acute renal failure Diseases 0.000 description 2
125000000539 amino acid group Chemical group 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
230000001851 biosynthetic effect Effects 0.000 description 2
239000005018 casein Substances 0.000 description 2
BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 2
235000021240 caseins Nutrition 0.000 description 2
230000002648 chondrogenic effect Effects 0.000 description 2
235000021277 colostrum Nutrition 0.000 description 2
210000003022 colostrum Anatomy 0.000 description 2
239000000539 dimer Substances 0.000 description 2
238000005516 engineering process Methods 0.000 description 2
238000011156 evaluation Methods 0.000 description 2
238000001914 filtration Methods 0.000 description 2
238000009472 formulation Methods 0.000 description 2
239000012634 fragment Substances 0.000 description 2
239000007943 implant Substances 0.000 description 2
238000001802 infusion Methods 0.000 description 2
230000000977 initiatory effect Effects 0.000 description 2
208000014674 injury Diseases 0.000 description 2
238000003780 insertion Methods 0.000 description 2
230000037431 insertion Effects 0.000 description 2
208000017169 kidney disease Diseases 0.000 description 2
230000000670 limiting effect Effects 0.000 description 2
238000012423 maintenance Methods 0.000 description 2
210000004962 mammalian cell Anatomy 0.000 description 2
238000001000 micrograph Methods 0.000 description 2
210000003205 muscle Anatomy 0.000 description 2
230000035772 mutation Effects 0.000 description 2
230000002988 nephrogenic effect Effects 0.000 description 2
239000000199 parathyroid hormone Substances 0.000 description 2
229960001319 parathyroid hormone Drugs 0.000 description 2
238000007911 parenteral administration Methods 0.000 description 2
238000004393 prognosis Methods 0.000 description 2
230000007425 progressive decline Effects 0.000 description 2
238000011160 research Methods 0.000 description 2
230000004044 response Effects 0.000 description 2
229910052708 sodium Inorganic materials 0.000 description 2
241000894007 species Species 0.000 description 2
238000001356 surgical procedure Methods 0.000 description 2
230000008733 trauma Effects 0.000 description 2
239000004474 valine Substances 0.000 description 2
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
YLOCGHYTXIINAI-XKUOMLDTSA-N (2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 YLOCGHYTXIINAI-XKUOMLDTSA-N 0.000 description 1
KLXQAXYSOJNJRI-KVTDHHQDSA-N (2s,3s,4r,5r)-5-amino-2,3,4,6-tetrahydroxyhexanal Chemical compound OC[C@@H](N)[C@@H](O)[C@H](O)[C@H](O)C=O KLXQAXYSOJNJRI-KVTDHHQDSA-N 0.000 description 1
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
102100028727 Bone morphogenetic protein 15 Human genes 0.000 description 1
102000003928 Bone morphogenetic protein 15 Human genes 0.000 description 1
108090000349 Bone morphogenetic protein 15 Proteins 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
241000283707 Capra Species 0.000 description 1
241000700198 Cavia Species 0.000 description 1
206010053567 Coagulopathies Diseases 0.000 description 1
102000016726 Coat Protein Complex I Human genes 0.000 description 1
108010092897 Coat Protein Complex I Proteins 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
208000032170 Congenital Abnormalities Diseases 0.000 description 1
CKLJMWTZIZZHCS-UWTATZPHSA-N D-aspartic acid Chemical compound OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 1
108020004414 DNA Proteins 0.000 description 1
BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
241000588724 Escherichia coli Species 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
206010016654 Fibrosis Diseases 0.000 description 1
206010018364 Glomerulonephritis Diseases 0.000 description 1
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
108010090290 Growth Differentiation Factor 2 Proteins 0.000 description 1
102000004858 Growth differentiation factor-9 Human genes 0.000 description 1
108090001086 Growth differentiation factor-9 Proteins 0.000 description 1
101710204281 Growth/differentiation factor 6 Proteins 0.000 description 1
102100039939 Growth/differentiation factor 8 Human genes 0.000 description 1
101000766116 Haloarcula vallismortis Cruxrhodopsin-3 Proteins 0.000 description 1
241000238631 Hexapoda Species 0.000 description 1
241000282412 Homo Species 0.000 description 1
101000695360 Homo sapiens Bone morphogenetic protein 15 Proteins 0.000 description 1
101000899368 Homo sapiens Bone morphogenetic protein 8B Proteins 0.000 description 1
101000893545 Homo sapiens Growth/differentiation factor 11 Proteins 0.000 description 1
101000848718 Homo sapiens Rap guanine nucleotide exchange factor 5 Proteins 0.000 description 1
101000651373 Homo sapiens Serine palmitoyltransferase small subunit B Proteins 0.000 description 1
102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
101710159910 Movement protein Proteins 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
108010056852 Myostatin Proteins 0.000 description 1
206010031240 Osteodystrophy Diseases 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
241001494479 Pecora Species 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
239000004365 Protease Substances 0.000 description 1
240000001987 Pyrus communis Species 0.000 description 1
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
206010062104 Renal mass Diseases 0.000 description 1
206010038481 Renal necrosis Diseases 0.000 description 1
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
102100027676 Serine palmitoyltransferase small subunit B Human genes 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
101710172711 Structural protein Proteins 0.000 description 1
241000282887 Suidae Species 0.000 description 1
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
239000004473 Threonine Substances 0.000 description 1
101100472152 Trypanosoma brucei brucei (strain 927/4 GUTat10.1) REL1 gene Proteins 0.000 description 1
108010046377 Whey Proteins Proteins 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
210000000577 adipose tissue Anatomy 0.000 description 1
230000002411 adverse Effects 0.000 description 1
235000004279 alanine Nutrition 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
235000009582 asparagine Nutrition 0.000 description 1
229960001230 asparagine Drugs 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
230000008901 benefit Effects 0.000 description 1
230000007698 birth defect Effects 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
210000000748 cardiovascular system Anatomy 0.000 description 1
108010027904 cartilage-derived-morphogenetic protein-2 Proteins 0.000 description 1
230000001925 catabolic effect Effects 0.000 description 1
239000006143 cell culture medium Substances 0.000 description 1
230000035602 clotting Effects 0.000 description 1
230000004186 co-expression Effects 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
239000002299 complementary DNA Substances 0.000 description 1
230000000536 complexating effect Effects 0.000 description 1
238000010668 complexation reaction Methods 0.000 description 1
238000004590 computer program Methods 0.000 description 1
238000009833 condensation Methods 0.000 description 1
230000005494 condensation Effects 0.000 description 1
239000002872 contrast media Substances 0.000 description 1
201000003146 cystitis Diseases 0.000 description 1
235000013365 dairy product Nutrition 0.000 description 1
230000007850 degeneration Effects 0.000 description 1
238000012217 deletion Methods 0.000 description 1
230000037430 deletion Effects 0.000 description 1
230000008021 deposition Effects 0.000 description 1
230000006866 deterioration Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
230000001079 digestive effect Effects 0.000 description 1
210000002249 digestive system Anatomy 0.000 description 1
230000010339 dilation Effects 0.000 description 1
239000000975 dye Substances 0.000 description 1
230000000694 effects Effects 0.000 description 1
230000003511 endothelial effect Effects 0.000 description 1
230000004761 fibrosis Effects 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
108020001507 fusion proteins Proteins 0.000 description 1
102000037865 fusion proteins Human genes 0.000 description 1
235000013922 glutamic acid Nutrition 0.000 description 1
239000004220 glutamic acid Substances 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
102000035122 glycosylated proteins Human genes 0.000 description 1
108091005608 glycosylated proteins Proteins 0.000 description 1
230000036449 good health Effects 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
230000036541 health Effects 0.000 description 1
239000000833 heterodimer Substances 0.000 description 1
239000000710 homodimer Substances 0.000 description 1
230000003054 hormonal effect Effects 0.000 description 1
102000043629 human RAPGEF5 Human genes 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
239000012216 imaging agent Substances 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
239000007928 intraperitoneal injection Substances 0.000 description 1
229960000310 isoleucine Drugs 0.000 description 1
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
230000002045 lasting effect Effects 0.000 description 1
229920002521 macromolecule Polymers 0.000 description 1
239000000463 material Substances 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
229930182817 methionine Natural products 0.000 description 1
239000011707 mineral Substances 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
210000004789 organ system Anatomy 0.000 description 1
230000003076 paracrine Effects 0.000 description 1
230000000737 periodic effect Effects 0.000 description 1
230000035699 permeability Effects 0.000 description 1
230000002688 persistence Effects 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
230000000704 physical effect Effects 0.000 description 1
230000004962 physiological condition Effects 0.000 description 1
210000000557 podocyte Anatomy 0.000 description 1
239000002243 precursor Substances 0.000 description 1
230000002028 premature Effects 0.000 description 1
230000008569 process Effects 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
108020001580 protein domains Proteins 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
210000005227 renal system Anatomy 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
230000028327 secretion Effects 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
230000005477 standard model Effects 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000008107 starch Substances 0.000 description 1
210000003699 striated muscle Anatomy 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
230000000451 tissue damage Effects 0.000 description 1
231100000827 tissue damage Toxicity 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
239000003053 toxin Substances 0.000 description 1
231100000765 toxin Toxicity 0.000 description 1
108700012359 toxins Proteins 0.000 description 1
238000013519 translation Methods 0.000 description 1
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
108010071304 univin Proteins 0.000 description 1
238000002562 urinalysis Methods 0.000 description 1
230000000007 visual effect Effects 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
235000021119 whey protein Nutrition 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Diabetes (AREA)
Epidemiology (AREA)
Immunology (AREA)
Urology & Nephrology (AREA)
Cardiology (AREA)
Hematology (AREA)
Obesity (AREA)
Orthopedic Medicine & Surgery (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Heart & Thoracic Surgery (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Saccharide Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Peptides Or Proteins (AREA)

ES97923567T 1996-05-06 1997-05-06 Terapias para la insuficiencia renal cronica. Expired - Lifetime ES2203803T3 (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US643321		1996-05-06
US08/643,321 US6498142B1 (en)	1996-05-06	1996-05-06	Morphogen treatment for chronic renal failure

Publications (1)

Publication Number	Publication Date
ES2203803T3 true ES2203803T3 (es)	2004-04-16

Family

ID=24580305

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
ES97923567T Expired - Lifetime ES2203803T3 (es)	1996-05-06	1997-05-06	Terapias para la insuficiencia renal cronica.
ES97922726T Expired - Lifetime ES2230604T3 (es)	1996-05-06	1997-05-06	Tratamiento morfogenetico de la insuficiencia renal cronica.

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
ES97922726T Expired - Lifetime ES2230604T3 (es)	1996-05-06	1997-05-06	Tratamiento morfogenetico de la insuficiencia renal cronica.

Country Status (11)

Country	Link
US (5)	US6498142B1 (2)
EP (2)	EP0914146B1 (2)
JP (4)	JP4766722B2 (2)
AT (2)	ATE277629T1 (2)
AU (2)	AU2832297A (2)
CA (2)	CA2254954C (2)
DE (2)	DE69730966T2 (2)
DK (2)	DK0910400T3 (2)
ES (2)	ES2203803T3 (2)
PT (2)	PT910400E (2)
WO (2)	WO1997041881A1 (2)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2363965C (en) *	1991-03-11	2010-05-18	Curis, Inc.	Protein-induced morphogenesis
US6077823A (en) *	1991-03-11	2000-06-20	Creative Biomolecules, Inc.	Method for reducing tissue damage associated with ischemia-reperfusion or hypoxia injury
US20030167492A1 (en)	1994-07-08	2003-09-04	Johns Hopkins University School Of Medicine	Transgenic non-human animals expressing a gdf-11 dominant negative polypeptide, and methods of making and using same
US6498142B1 (en) *	1996-05-06	2002-12-24	Curis, Inc.	Morphogen treatment for chronic renal failure
WO1998050060A1 (en)	1997-05-05	1998-11-12	Creative Biomolecules, Inc.	Therapies for acute renal failure
WO1998050061A1 (en) *	1997-05-07	1998-11-12	Biogen, Inc.	Novel therapies for cystic kidney disease
EP0896825B1 (en)	1997-08-14	2002-07-17	Sulzer Innotec Ag	Composition and device for in vivo cartilage repair comprising nanocapsules with osteoinductive and/or chondroinductive factors
US6203788B1 (en) *	1997-09-29	2001-03-20	Adherex Inc.	Compounds and methods for regulating cell adhesion
CA2314423A1 (en) *	1997-12-04	1999-06-10	Creative Biomolecules, Inc.	Maintenance of smooth muscle integrity by morphogenic proteins
AU765832B2 (en) *	1998-07-28	2003-10-02	Johns Hopkins University School Of Medicine, The	Growth differentiation factor-11
US7087577B2 (en) *	1998-10-16	2006-08-08	Zimmer Orthobiologies, Inc.	Method of promoting natural bypass
US6992066B2 (en)	1998-10-16	2006-01-31	Zimmer Orthobiologics, Inc.	Povidone-containing carriers for polypeptide growth factors
ES2263485T3 (es) *	1999-09-14	2006-12-16	Biogen Idec Ma Inc.	Terapia para insuficiencia renal cronica utilizando uno o mas angtagonistas de integrinas.
US20020173453A1 (en) *	2000-12-15	2002-11-21	Rama Akella	Method of treating renal injury
US7700819B2 (en)	2001-02-16	2010-04-20	Kci Licensing, Inc.	Biocompatible wound dressing
US7763769B2 (en)	2001-02-16	2010-07-27	Kci Licensing, Inc.	Biocompatible wound dressing
US7232802B2 (en) *	2001-12-21	2007-06-19	Zimmer Orthobiologics, Inc.	Compositions and methods for promoting myocardial and peripheral angiogenesis
US7622562B2 (en)	2002-06-26	2009-11-24	Zimmer Orthobiologics, Inc.	Rapid isolation of osteoinductive protein mixtures from mammalian bone tissue
US20050272649A1 (en) *	2002-08-28	2005-12-08	Hruska Keith A	Conjoint administration of morphogens and ACE inhibitors in treatment of chronic renal failure
EP1677735B1 (en)	2003-10-17	2014-07-23	Joslin Diabetes Center, Inc.	Methods and compositions for modulating adipocyte function
US7844367B2 (en)	2003-12-23	2010-11-30	Rain Bird Corporation	Code replacement for irrigation controllers
BRPI0509331B8 (pt) *	2004-03-30	2021-05-25	Ilypsa Inc	uso de uma composição de ligação de sódio
US7459527B2 (en) *	2004-03-31	2008-12-02	Xencor, Inc.	BMP-7 variants with improved properties
US20100150885A1 (en)	2005-06-01	2010-06-17	Joslin Diabetes Center, Inc.	Methods and compositions for inducing brown adipogenesis
US7771995B2 (en) *	2005-11-14	2010-08-10	Merial Limited	Plasmid encoding human BMP-7
EP3147296A1 (en)	2005-11-14	2017-03-29	Merial, Inc.	Gene therapy for renal failure
JP2009524436A (ja) *	2006-01-24	2009-07-02	ノースフィールドラボラトリーズ、インコーポレイテッド	重合したヘモグロビンの培地、並びに島細胞の単離及び移植におけるその使用
US20090004159A1 (en) *	2006-01-24	2009-01-01	The Board Of Trustees Of The University Of Illinoi	Polymerized Hemoglobin Media and Its Use in Isolation and Transplantation of Islet Cells
US20080090765A1 (en) *	2006-05-25	2008-04-17	The Trustees Of Columbia University In The City Of New York	Compositions for modulating growth of embryonic and adult kidney tissue and uses for treating kidney damage
WO2007137584A1 (en)	2006-05-30	2007-12-06	Antibodyshop A/S	Methods and devices for rapid assessment of severity of injury
US7722665B2 (en)	2006-07-07	2010-05-25	Graft Technologies, Inc.	System and method for providing a graft in a vascular environment
US8025881B2 (en)	2006-07-21	2011-09-27	Chugai Seiyaku Kabushiki Kaisha	BMP antibodies and methods of treating kidney disease using the same
WO2008075173A2 (en) *	2006-12-15	2008-06-26	Ruprecht-Karls-Universität Heidelberg	Methods for treating podocyte-related disorders
WO2008134297A2 (en) *	2007-04-24	2008-11-06	Johnson & Johnson Regenerative Therapeutics, Llc	Engineered renal tissue
DE102007034580B4 (de) *	2007-07-13	2012-11-08	NMI Naturwissenschaftliches und Medizinisches Institut an der Universität Tübingen	Biomaterial basierend auf einem hydrophilen polymeren Träger
US20090155245A1 (en) *	2007-12-18	2009-06-18	Fang Carrie H	Treatment for Organ Regeneration with Combination of Drug and Biologics
CN102083969A (zh) *	2008-05-06	2011-06-01	乔斯林糖尿病中心股份有限公司	诱导褐色脂肪形成的方法和组合物
JP5485885B2 (ja) *	2008-06-24	2014-05-07	株式会社根本杏林堂	薬液注入装置、この薬液注入装置を有する透視撮像システム、薬液注入装置のコンピュータプログラムおよびデータ処理方法
JP2012501456A (ja) *	2008-08-28	2012-01-19	アスチュートメディカル，インコーポレイテッド	腎損傷および腎不全の診断および予後のための方法および組成物
EP2324354B1 (en) *	2008-08-29	2014-07-16	Astute Medical, Inc.	Methods for prognosis of acute renal failure
ES2836218T3 (es)	2008-10-21	2021-06-24	Astute Medical Inc	Procedimientos y composiciones para el diagnóstico y pronóstico de lesión renal e insuficiencia renal
CA2740923A1 (en) *	2008-10-21	2010-04-29	Astute Medical, Inc.	Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EP2913676A1 (en)	2008-11-10	2015-09-02	Astute Medical, Inc.	Methods and compositions for diagnosis and prognosis of renal injury and renal failure
AU2009316387B2 (en) *	2008-11-22	2015-01-29	Astute Medical, Inc.	Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US9229010B2 (en)	2009-02-06	2016-01-05	Astute Medical, Inc.	Methods and compositions for diagnosis and prognosis of renal injury and renal failure
AU2010279249B2 (en)	2009-02-06	2015-08-13	Astute Medical, Inc.	Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CN102369293B (zh) *	2009-02-06	2014-05-28	阿斯图特医药公司	肾损伤和肾衰竭的诊断及预后
SG173634A1 (en) *	2009-02-12	2011-09-29	Stryker Corp	COMPOSITIONS AND METHODS FOR MINIMALLY-INVASIVE SYSTEMIC DELIVERY OF PROTEINS INCLUDING TGF-ß SUPERFAMILY MEMBERS
WO2010093925A2 (en)	2009-02-12	2010-08-19	Stryker Corporation	PERIPHERAL ADMINISTRATION OF PROTEINS INCLUDING TGF-β SUPERFAMILY MEMBERS FOR TREATMENT OF SYSTEMIC DISORDERS AND DISEASE
WO2010103070A2 (en)	2009-03-12	2010-09-16	Charité - Universitätsmedizin Berlin	Bone morphogenetic protein 2 (bmp2) variants with reduced bmp antagonist sensitivity
WO2010144696A1 (en)	2009-06-11	2010-12-16	Burnham Institute For Medical Research	Directed differentiation of stem cells
EP2352750B1 (en)	2009-09-17	2012-06-13	Stryker Corporation	Buffers for controlling the ph of bone morphogenetic proteins
AU2010315008B2 (en)	2009-11-07	2015-12-03	Astute Medical, Inc.	Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2011075744A1 (en)	2009-12-20	2011-06-23	Astute Medical, Inc.	Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2011087768A1 (en)	2009-12-22	2011-07-21	Stryker Corporation	Bmp-7 variants with reduced immunogenicity
AU2011213684B2 (en)	2010-02-05	2014-11-20	Astute Medical, Inc.	Methods and compositions for diagnosis and prognosis of renal injury and renal failure
NZ701807A (en)	2010-02-26	2015-05-29	Astute Medical Inc	Methods and compositions for diagnosis and prognosis of renal injury and renal failure
ES2667066T3 (es)	2010-05-24	2018-05-09	The Trustees Of Columbia University In The City Of New York	Proteínas NGAL mutantes y usos de las mismas
NZ605698A (en)	2010-06-23	2015-03-27	Astute Medical Inc	Methods and compositions for diagnosis and prognosis of renal injury and renal failure
IN2012MN02812A (2)	2010-06-23	2015-05-22	Astute Medical Inc
PH12013500294A1 (en)	2010-08-20	2017-08-23	Wyeth Llc	Designer osteogenic proteins
US9688735B2 (en)	2010-08-20	2017-06-27	Wyeth Llc	Designer osteogenic proteins
US10935548B2 (en)	2011-12-08	2021-03-02	Astute Medical, Inc.	Methods for diagnosis and prognosis of renal injury and renal failure using insulin-like growth factor-binding protein 7 and metalloproteinase inhibitor 2
JP6475624B2 (ja)	2012-10-08	2019-02-27	レリプサ，インコーポレイテッド	高血圧症及び高カリウム血症を治療するためのカリウム結合剤
EP2925337B1 (en)	2012-11-21	2019-07-03	The Trustees of Columbia University in the City of New York	Mutant ngal proteins and uses thereof
EP3361255B1 (en)	2013-01-17	2020-03-11	Astute Medical, Inc.	Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US8945872B2 (en)	2013-01-25	2015-02-03	Warsaw Orthopedic, Inc.	Methods of purifying human recombinant growth and differentiation factor-5 (rhGDF-5) protein
US9051389B2 (en)	2013-01-25	2015-06-09	Warsaw Orthopedic, Inc.	Expression conditions and methods of human recombinant growth and differentiation factor-5 (rhGDF-5)
US9169308B2 (en)	2013-01-25	2015-10-27	Warsaw Orthopedic, Inc.	Methods and compositions of human recombinant growth and differentiation factor-5 (rhGDF-5) isolated from inclusion bodies
US9359417B2 (en)	2013-01-25	2016-06-07	Warsaw Orthopedic, Inc.	Cell cultures and methods of human recombinant growth and differentiaton factor-5 (rhGDF-5)
US8956829B2 (en)	2013-01-25	2015-02-17	Warsaw Orthopedic, Inc.	Human recombinant growth and differentiaton factor-5 (rhGDF-5)
EP2784083A1 (en)	2013-03-28	2014-10-01	Charité - Universitätsmedizin Berlin	Bone Morphogenetic Protein (BMP) variants with highly reduced antagonist sensitivity and enhanced specific biological activity
US10539588B2 (en) *	2013-11-11	2020-01-21	General Electric Company	Method for reducing error in rotor speed measurements
EP2944326B1 (en)	2014-05-16	2018-11-21	Cyanagen Srl	Tricarbocyanine-cyclodextrin-conjugates and their use for the diagnosis of kidney diseases
JP7199809B2 (ja)	2015-02-13	2023-01-06	ファクターバイオサイエンスインコーポレイテッド	核酸製品及びその投与方法
EP3465201A4 (en)	2016-06-06	2020-08-26	Astute Medical, Inc.	MANAGEMENT OF ACUTE KIDNEY DAMAGE USING INSULINOMIMETIC GROWTH FACTOR BINDING PROTEIN 7 AND TISSUE METALLOPROTEINASE 2 INHIBITOR
US10576167B2 (en)	2016-08-17	2020-03-03	Factor Bioscience Inc.	Nucleic acid products and methods of administration thereof
JP2019039673A (ja) *	2017-08-22	2019-03-14	セイコーエプソン株式会社	時間デジタル変換回路、回路装置、物理量測定装置、電子機器及び移動体

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IT1156741B (it) *	1978-05-15	1987-02-04	Sigma Tau Ind Farmaceuti	Applicazione terapeutica della carnitina e di alcuni derivati acilati della carnitina nell'emodialisi
US4342828A (en)	1979-07-20	1982-08-03	Morinaga Milk Industry Co., Ltd.	Method for producing substance capable of stimulating differentiation and proliferation of human granulopoietic stem cells
US4627839A (en)	1985-11-21	1986-12-09	American Hospital Supply Corporation	Patient controlled analgesia conversion
IL83003A (en)	1986-07-01	1995-07-31	Genetics Inst	Osteoinductive factors
US5013649A (en)	1986-07-01	1991-05-07	Genetics Institute, Inc.	DNA sequences encoding osteoinductive products
US5011691A (en)	1988-08-15	1991-04-30	Stryker Corporation	Osteogenic devices
US5266683A (en)	1988-04-08	1993-11-30	Stryker Corporation	Osteogenic proteins
US5045452A (en)	1988-09-02	1991-09-03	Brigham And Women's Hospital	Method for evaluating nephrotoxicity
DE69031939T2 (de)	1989-03-28	1998-09-10	Genetics Institute, Inc., Cambridge, Mass.	Osteoinduktive zusammensetzungen
JPH06500991A (ja)	1990-05-16	1994-01-27	ジェネティックス・インスティテュート・インコーポレイテッド	骨および軟骨誘導蛋白質
JPH0426624A (ja) *	1990-05-18	1992-01-29	Tsumura & Co	慢性腎不全改善剤
JPH05509086A (ja) *	1990-06-22	1993-12-16	イー・アイ・デュポン・ドゥ・ヌムール・アンド・カンパニー	イミダゾールアンジオテンシン―２受容体拮抗薬による慢性腎不全の治療
WO1992015323A1 (en)	1991-03-11	1992-09-17	Creative Biomolecules, Inc.	Protein-induced morphogenesis
CA2363965C (en)	1991-03-11	2010-05-18	Curis, Inc.	Protein-induced morphogenesis
US5849686A (en) *	1991-03-11	1998-12-15	Creative Biomolecules, Inc.	Morphogen-induced liver regeneration
US6194376B1 (en)	1991-03-11	2001-02-27	Creative Biomolecules, Inc.	Method for modulating inflammatory response comprising administering morphogen
US6077823A (en) *	1991-03-11	2000-06-20	Creative Biomolecules, Inc.	Method for reducing tissue damage associated with ischemia-reperfusion or hypoxia injury
US7056882B2 (en)	1991-03-11	2006-06-06	Curis, Inc.	Treatment to prevent loss of and/or increase bone mass in metabolic bone diseases
US6287816B1 (en)	1991-06-25	2001-09-11	Genetics Institute, Inc.	BMP-9 compositions
ATE192931T1 (de)	1991-08-30	2000-06-15	Creative Biomolecules Inc	Morphogen-induzierte modulation von entzündlichen antworten
EP0601129B1 (en)	1991-08-30	2000-11-15	Creative Biomolecules, Inc.	Morphogenic protein screening method
DE69233559T2 (de)	1991-08-30	2006-08-31	Curis, Inc., Cambridge	Osteogenische proteine in der behandlung von metabolischen knochenkrankheiten
US6120760A (en) *	1992-02-12	2000-09-19	Biopharm Gesellschaft Zur Biotechnologischen Entwicklung	Growth/differentiation factors of the TGF-β family
JPH07509720A (ja)	1992-07-31	1995-10-26	クリエイティブ　バイオモレキュルズ，インコーポレイテッド	モルフォゲン強化栄養組成物
EP0653942B2 (en)	1992-07-31	2007-03-07	Curis, Inc.	Morphogen-induced nerve regeneration and repair
ATE287949T1 (de)	1992-07-31	2005-02-15	Stryker Corp	Löslicher komplex morphogener proteine und zusammensetzungen davon
ES2114073T3 (es)	1992-09-16	1998-05-16	Creative Biomolecules Inc	Regeneracion del higado inducida por morfogenes.
JPH08503198A (ja)	1992-11-03	1996-04-09	クリエイティブバイオモレキュルズ，インコーポレイテッド	Ｏｐ−３誘導形態形成
US5372335A (en)	1992-12-18	1994-12-13	Scott H. Yenzer	Aerial marker ball and method of placement
JPH08510446A (ja)	1993-03-04	1996-11-05	クリエイティブバイオモレキュルズ，インコーポレイテッド	組換え骨形成タンパク質を生成するための方法および組成物
US5631159A (en)	1993-09-22	1997-05-20	Creative Biomolecules, Inc.	Lipid-modified serum free media
US5585237A (en)	1993-10-25	1996-12-17	Creative Biomolecules, Inc.	Methods and compositions for high protein production from recombinant DNA
JPH09509141A (ja) *	1993-11-15	1997-09-16	セルトリックスファーマシューティカルズ，インコーポレイテッド	Ｉｇｆ‐ｉおよびｉｇｆｂｐ‐３を投与することによる腎臓疾患処置の方法
US5525621A (en) *	1994-05-20	1996-06-11	Cytos Pharmaceuticals Llc	Imidazole derivatives as protective agents in reperfusion injury and severe inflammatory responses
US5714511A (en)	1995-07-31	1998-02-03	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Selective prevention of organ injury in sepsis and shock using selection release of nitric oxide in vulnerable organs
US5723411A (en) *	1995-10-31	1998-03-03	E. I. Du Pont De Nemours And Company	Herbicidal pyridazinones
KR20000064752A (ko)	1996-03-22	2000-11-06	더 제네랄 호스피탈 코포레이션	중추신경계허혈또는외상의발현후폴리펩티드성장인자를투여하는방법
US5820589A (en)	1996-04-30	1998-10-13	Medtronic, Inc.	Implantable non-invasive rate-adjustable pump
US6498142B1 (en)	1996-05-06	2002-12-24	Curis, Inc.	Morphogen treatment for chronic renal failure
US5879908A (en) *	1997-04-30	1999-03-09	Smithkline Beecham Corporation	CRFG-1a, a target and marker for chronic renal failure
US7147839B2 (en) *	1998-05-29	2006-12-12	Curis, Inc.	Methods for evaluating tissue morphogenesis and activity

1996
- 1996-05-06 US US08/643,321 patent/US6498142B1/en not_active Expired - Lifetime
1997
- 1997-05-06 DK DK97923567T patent/DK0910400T3/da active
- 1997-05-06 WO PCT/US1997/007816 patent/WO1997041881A1/en not_active Ceased
- 1997-05-06 WO PCT/US1997/007655 patent/WO1997041880A1/en not_active Ceased
- 1997-05-06 US US08/851,628 patent/US6861404B1/en not_active Expired - Fee Related
- 1997-05-06 DE DE69730966T patent/DE69730966T2/de not_active Expired - Lifetime
- 1997-05-06 DE DE69723845T patent/DE69723845T2/de not_active Expired - Lifetime
- 1997-05-06 CA CA002254954A patent/CA2254954C/en not_active Expired - Fee Related
- 1997-05-06 PT PT97923567T patent/PT910400E/pt unknown
- 1997-05-06 EP EP97922726A patent/EP0914146B1/en not_active Expired - Lifetime
- 1997-05-06 JP JP54021197A patent/JP4766722B2/ja not_active Expired - Fee Related
- 1997-05-06 EP EP97923567A patent/EP0910400B1/en not_active Expired - Lifetime
- 1997-05-06 ES ES97923567T patent/ES2203803T3/es not_active Expired - Lifetime
- 1997-05-06 AU AU28322/97A patent/AU2832297A/en not_active Abandoned
- 1997-05-06 ES ES97922726T patent/ES2230604T3/es not_active Expired - Lifetime
- 1997-05-06 CA CA002254953A patent/CA2254953C/en not_active Expired - Fee Related
- 1997-05-06 AT AT97922726T patent/ATE277629T1/de active
- 1997-05-06 DK DK97922726T patent/DK0914146T3/da active
- 1997-05-06 AT AT97923567T patent/ATE245997T1/de not_active IP Right Cessation
- 1997-05-06 AU AU29339/97A patent/AU2933997A/en not_active Abandoned
- 1997-05-06 PT PT97922726T patent/PT914146E/pt unknown
- 1997-05-06 JP JP09540150A patent/JP2000510835A/ja active Pending
2004
- 2004-12-17 US US11/016,499 patent/US7524817B2/en not_active Expired - Fee Related
2009
- 2009-03-16 US US12/404,559 patent/US8017580B2/en not_active Expired - Fee Related
- 2009-05-26 JP JP2009126963A patent/JP5247593B2/ja not_active Expired - Fee Related
2011
- 2011-08-11 US US13/207,584 patent/US8377878B2/en not_active Expired - Fee Related
2012
- 2012-08-14 JP JP2012179876A patent/JP2012229268A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
EP0914146B1 (en)	2004-09-29
WO1997041881A1 (en)	1997-11-13
DE69723845T2 (de)	2004-06-03
JP4766722B2 (ja)	2011-09-07
PT910400E (pt)	2003-12-31
JP2009185076A (ja)	2009-08-20
ES2230604T3 (es)	2005-05-01
JP2000510835A (ja)	2000-08-22
US8377878B2 (en)	2013-02-19
US8017580B2 (en)	2011-09-13
ATE245997T1 (de)	2003-08-15
JP5247593B2 (ja)	2013-07-24
WO1997041880A1 (en)	1997-11-13
US6498142B1 (en)	2002-12-24
US20100291170A1 (en)	2010-11-18
CA2254954C (en)	2010-01-12
DK0914146T3 (da)	2005-01-31
CA2254953A1 (en)	1997-11-13
JP2000510124A (ja)	2000-08-08
ATE277629T1 (de)	2004-10-15
US20050143304A1 (en)	2005-06-30
CA2254954A1 (en)	1997-11-13
DE69723845D1 (de)	2003-09-04
JP2012229268A (ja)	2012-11-22
CA2254953C (en)	2006-09-26
DE69730966D1 (de)	2004-11-04
EP0914146A1 (en)	1999-05-12
EP0910400A1 (en)	1999-04-28
US6861404B1 (en)	2005-03-01
DE69730966T2 (de)	2006-02-23
AU2832297A (en)	1997-11-26
PT914146E (pt)	2005-02-28
AU2933997A (en)	1997-11-26
DK0910400T3 (da)	2003-11-24
US20120004171A1 (en)	2012-01-05
US7524817B2 (en)	2009-04-28
EP0910400B1 (en)	2003-07-30

Publication	Publication Date	Title
ES2203803T3 (es)	2004-04-16	Terapias para la insuficiencia renal cronica.
US8748378B2 (en)	2014-06-10	Therapies for acute renal failure
ES2201287T5 (es)	2007-10-16	Metodo para mejorar la recuperacion funcional de la coordinacion motora, del habla o la percepcion sensorial tras una isquemia o trauma del sistema nervioso central.
JP2013137314A (ja)	2013-07-11	組織形態形成および活性を評価するための方法
AU757969B2 (en)	2003-03-13	Therapies for chronic renal failure
AU767112B2 (en)	2003-10-30	Morphogen treatment for chronic renal failure
AU3433902A (en)	2002-06-06	Therapies for acute renal failure